ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NVAX Novavax Inc

4.90
0.19 (4.03%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novavax Inc NASDAQ:NVAX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.19 4.03% 4.90 4.77 5.00 4.94 4.6895 4.84 4,668,267 05:00:08

Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 9, 2016

02/08/2016 9:05pm

GlobeNewswire


GAITHERSBURG, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its second quarter 2016 financial and operating results after the close of U.S. financial markets on Tuesday, August 9, 2016.

Management will host a conference call to discuss the quarterly financial results and provide an update on corporate activities.

Conference call details are as follows:

Date: Tuesday, August 9, 2016
Time: 4:30 p.m. U.S. Eastern Time (ET)
Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode: 59901631
Via web: www.novavax.com, "Investors"/ "Events"
   

Conference call replay:

Date: Starting at 7:30 p.m. ET, August 9, 2016 until August 16, 2016
Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode: 59901631
Via web: www.novavax.com, "Investors"/ "Events"
   

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Contact: 
Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

ir@novavax.com
240-268-2000




This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

HUG#2032723

1 Year Novavax Chart

1 Year Novavax Chart

1 Month Novavax Chart

1 Month Novavax Chart

Your Recent History

Delayed Upgrade Clock